Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and other Small Molecule Kinase Inhibitors - United States, July 2016-June 2019.

Jeremy A W GoldSeda S ToluTom ChillerKaitlin BenedictBrendan R Jackson

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)

We analyzed administrative data to determine the one-year incidence of invasive fungal infections (IFI) in patients initiating small molecule kinase inhibitor (SMKI) therapy. IFI incidence by SMKI ranged from 0.0 to 10.6%, with patients on midostaurin having the highest incidence. Thirty-eight (3.0%) of 1286 patients on ibrutinib developed an IFI.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
risk factors
prognostic factors
stem cells
machine learning
bone marrow
replacement therapy